All In Biotech

Drug Trial Radar · NCT05405595

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Jun 15, 2022

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Adagene IncIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • ADG126Drug

    ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.

  • Pembrolizumab (KEYTRUDA®)Drug

    Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).

  • Standard of Care (Trifluridine/Tipiracil-Bevacizumab)Drug

    The standard of care therapies will include Trifluridine/Tipiracil-Bevacizumab, approved for treating metastatic colorectal cancer (CRC)and various solid tumors.

  • Standard of care (Fruquintinib)Drug

    The standard of care therapy, Fruquintinib, is approved for treating metastatic colorectal cancer (CRC) and various solid tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.Time frame: 9 months
  2. the safety and tolerability of ADG126 at escalating dose level in combination with pembrolizumab in adults with advanced metastatic solid tumorsTime frame: 9 months
  3. Access the preliminary antitumor activity of ADG126-pembrolizumab combination regimensTime frame: 9 months
  4. Maximum tolerated dose (MTD) and/or RP2D for ADG126 with Trifluridine/Tipiracil-BevacizumabTime frame: 6 months
  5. Access the preliminary antitumor activity of ADG126 with Pembrolizumab in combination standard of careTime frame: 6 months
  6. Access and characterize the optimal dose based on safety and efficacy parametersTime frame: 9 months

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • City of Hope Orange County

    Irvine, California · Recruiting

  • Florida cancer specialist/Sarah Cannon Research Institute

    Sarasota, Florida · Active not recruiting

  • The Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • SunYat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Hong Kong Humanity & Health Clinical Trial Center

    Hong Kong, Hong Kong, China · Recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong, China · Recruiting

  • Keimyung University Dongsan Hospital

    Daegu, South Korea · Terminated

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • KangBuk Samsung Hospital

    Seoul, South Korea · Terminated

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Dong -A University Hospital

    Seogu, Busan Gwangyeogsi, South Korea · Terminated

  • CHA Bundang Medical Center, CHA university

    Seongnam, Gyeonggido, South Korea · Recruiting

  • The Catholic University of Korea Street. Vincent Hospital

    Suwon, Gyeonggido, South Korea · Terminated

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.